Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place and Product with Price and Volume Outlook with Executive and Consultant Guides 2023 to 2027
“Liquid biopsy crosses the chasm to a new growth phase”
Publication date: January 11, 2023
Page count: 533
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all cancer types using a single blood test.
Illumina is now working on the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has moved out of the development phase and into the growth phase. The impact on the healthcare industry is enormous.
This latest edition includes revenues, volume and price forecasts to 2027 across the following:
- Other (can be broken down for specific cancer types on request)
- Screening / early detection
- Therapy selection
- Recurrance monitoring
- Hospital laboratory
- Laboratory service
- Outpatient laboratory
- Circulating tumor cell (CTC)
- Cell-free DNA (CfDNA)
- Rest of Europe (breakouts available)
- South Korea
- Rest of APAC (breakouts available)
- Rest of Latin America (breakouts available)
- Middle East and Africa (breakouts available)
Find the opportunities and the pitfalls, understand growth expectations and the ultimate potential market size.
Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Check all your licensing options however your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as additional assistance and breakout data is included with each corporate license as standard.
All report data is available in Excel format on request with the corporate license.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell is a member of The American Association for Clinical Chemistry. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School